PrEP is a medication approved by the Food and Drug Administration for the prevention of HIV among people exposed to HIV through sex or drugs.
Have sex or use drugs? Anyone who is sexually active or uses drugs can benefit from PrEP! Studies show that PrEP reduces the risk of getting HIV by 99% when taken as prescribed.
PRIME is a PrEP adherence study for men who use meth and aims to reduce HIV risk. The study is conducted by the Center on Substance Use and Health of the San Francisco Department of Public Health.
This study may be for you if you are:
-Assigned male at birth
-Living in California
Participants in PRIME will receive free oral Descovy PrEP from the study, or oral PrEP from their own provider.
All participants will receive counseling to help take PrEP on a daily basis to reduce HIV.
Half of the participants will be asked to use a video app to record taking PrEP. Participants in the video group will receive additional payments for completing and uploading these videos.
PRIME is a 6 month study. People in the San Francisco Bay Area would be asked to come to our office in San Francisco up to 6 times during the study. For those in another part of California, we would have the visits via Zoom.
Your time and participation is valuable to us and advances public health research.
If eligible, you would receive between $580-$1199 depending on which study arm you are assigned to.
To determine if you are eligible to participate, call us at 628-217-6319 or send us your contact information using the contact form on this page.
We follow strict HIPAA regulations and good clinical practices to ensure the safety and confidentiality of all participants in our study.
If you are eligible, we will set up the first screening visit for you to come in to our office, or a virtual visit if you live in another part of California. This visit is to see if you meet further study criteria. Determining study eligibility involves meeting with a research associate, clinical staff and various other procedures, which will be explained to you during the informed consent process.
Since the study is investigating approaches to support the use of an HIV prevention drug, this study is open to HIV-negative participants only. However, the Center on Substance Use and Health does conduct other research that is open for individuals regardless of their HIV status. For more information on our Center, please visit www.csuhsf.org